LBA7_PR - NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC
Publication/Presentation Date
10-2016
Volume
27
Issue
Sup 6
Published In/Presented At
Disciplines
Medicine and Health Sciences
Department(s)
Department of Medicine, Hematology-Medical Oncology Division
Document Type
Article
COinS